Cargando…
Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301)
BACKGROUND: Preoperative chemoradiotherapy (CRT), the current standard of care for locally advanced rectal cancer (LARC), is associated with many radiotherapy (RT)-related side effects. We aimed to evaluate whether S-1 and oxaliplatin (SOX) or folinic acid, 5-FU, and oxaliplatin (mFOLFOX6) can be as...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786922/ https://www.ncbi.nlm.nih.gov/pubmed/33402130 http://dx.doi.org/10.1186/s12885-020-07766-5 |
_version_ | 1783632726038937600 |
---|---|
author | Miwa, Keisuke Oki, Eiji Enomoto, Masanobu Ihara, Keisuke Ando, Koji Fujita, Fumihiko Tominaga, Masahiro Mori, Shinichiro Nakayama, Goro Shimokawa, Mototsugu Saeki, Hiroshi Baba, Hideo Mori, Masaki Akagi, Yoshito |
author_facet | Miwa, Keisuke Oki, Eiji Enomoto, Masanobu Ihara, Keisuke Ando, Koji Fujita, Fumihiko Tominaga, Masahiro Mori, Shinichiro Nakayama, Goro Shimokawa, Mototsugu Saeki, Hiroshi Baba, Hideo Mori, Masaki Akagi, Yoshito |
author_sort | Miwa, Keisuke |
collection | PubMed |
description | BACKGROUND: Preoperative chemoradiotherapy (CRT), the current standard of care for locally advanced rectal cancer (LARC), is associated with many radiotherapy (RT)-related side effects. We aimed to evaluate whether S-1 and oxaliplatin (SOX) or folinic acid, 5-FU, and oxaliplatin (mFOLFOX6) can be as effective as neoadjuvant chemotherapy (NAC) regimens for LARC without RT. METHODS: Patients with untreated resectable LARC were randomly assigned to receive SOX or mFOLFOX6. The NAC protocol period was 3 months. The primary endpoint was 3-year disease-free survival (DFS), and the secondary endpoints included pathological effects, surgical completion rate, 3-year survival, and safety. RESULTS: From September 2013 to October 2015, 56 and 54 patients were enrolled in the SOX and mFOLFOX6 arms, respectively. The 3-year DFS rates were 69.4% (95% confidence interval [CI] 54.9–83.6) and 73.4% (95% CI 58.7–83.6) in the SOX and mFOLFOX6 arms, respectively; no significant differences were found between the arms (log-rank test; P = 0.5315, hazard ratio: 0.808, 95% CI 0.414–1.578). The 3-year survival rates were 92.3 and 91.8% in the SOX and mFOLFOX6 arms, respectively. The surgical completion rate was 98.1% overall, 100% in the SOX arm, and 96.0% in the mFOLFOX6 arm. The incidences of pathological response rates ≥grade 1b were 41.5 and 43.8% in the SOX and mFOLFOX6 arms, respectively. Both treatments were manageable and tolerable. CONCLUSION: We demonstrated the effectiveness and safety of SOX and mFOLFOX6, both of which may be new neoadjuvant treatment candidates in previously untreated LARC cases. TRIAL REGISTRATION: Date of enrolment of the first participant to the trial: 3rd Oct 2013; This study was registered in the UMIN clinical trials registry on 14th Aug, 2013. (Prospectively registered, UMIN-CTR number UMIN000011486). https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&recptno=R000013441&language=J |
format | Online Article Text |
id | pubmed-7786922 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-77869222021-01-07 Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301) Miwa, Keisuke Oki, Eiji Enomoto, Masanobu Ihara, Keisuke Ando, Koji Fujita, Fumihiko Tominaga, Masahiro Mori, Shinichiro Nakayama, Goro Shimokawa, Mototsugu Saeki, Hiroshi Baba, Hideo Mori, Masaki Akagi, Yoshito BMC Cancer Research Article BACKGROUND: Preoperative chemoradiotherapy (CRT), the current standard of care for locally advanced rectal cancer (LARC), is associated with many radiotherapy (RT)-related side effects. We aimed to evaluate whether S-1 and oxaliplatin (SOX) or folinic acid, 5-FU, and oxaliplatin (mFOLFOX6) can be as effective as neoadjuvant chemotherapy (NAC) regimens for LARC without RT. METHODS: Patients with untreated resectable LARC were randomly assigned to receive SOX or mFOLFOX6. The NAC protocol period was 3 months. The primary endpoint was 3-year disease-free survival (DFS), and the secondary endpoints included pathological effects, surgical completion rate, 3-year survival, and safety. RESULTS: From September 2013 to October 2015, 56 and 54 patients were enrolled in the SOX and mFOLFOX6 arms, respectively. The 3-year DFS rates were 69.4% (95% confidence interval [CI] 54.9–83.6) and 73.4% (95% CI 58.7–83.6) in the SOX and mFOLFOX6 arms, respectively; no significant differences were found between the arms (log-rank test; P = 0.5315, hazard ratio: 0.808, 95% CI 0.414–1.578). The 3-year survival rates were 92.3 and 91.8% in the SOX and mFOLFOX6 arms, respectively. The surgical completion rate was 98.1% overall, 100% in the SOX arm, and 96.0% in the mFOLFOX6 arm. The incidences of pathological response rates ≥grade 1b were 41.5 and 43.8% in the SOX and mFOLFOX6 arms, respectively. Both treatments were manageable and tolerable. CONCLUSION: We demonstrated the effectiveness and safety of SOX and mFOLFOX6, both of which may be new neoadjuvant treatment candidates in previously untreated LARC cases. TRIAL REGISTRATION: Date of enrolment of the first participant to the trial: 3rd Oct 2013; This study was registered in the UMIN clinical trials registry on 14th Aug, 2013. (Prospectively registered, UMIN-CTR number UMIN000011486). https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&recptno=R000013441&language=J BioMed Central 2021-01-05 /pmc/articles/PMC7786922/ /pubmed/33402130 http://dx.doi.org/10.1186/s12885-020-07766-5 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Miwa, Keisuke Oki, Eiji Enomoto, Masanobu Ihara, Keisuke Ando, Koji Fujita, Fumihiko Tominaga, Masahiro Mori, Shinichiro Nakayama, Goro Shimokawa, Mototsugu Saeki, Hiroshi Baba, Hideo Mori, Masaki Akagi, Yoshito Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301) |
title | Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301) |
title_full | Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301) |
title_fullStr | Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301) |
title_full_unstemmed | Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301) |
title_short | Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301) |
title_sort | randomized phase ii study comparing the efficacy and safety of sox versus mfolfox6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (kscc1301) |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786922/ https://www.ncbi.nlm.nih.gov/pubmed/33402130 http://dx.doi.org/10.1186/s12885-020-07766-5 |
work_keys_str_mv | AT miwakeisuke randomizedphaseiistudycomparingtheefficacyandsafetyofsoxversusmfolfox6asneoadjuvantchemotherapywithoutradiotherapyforlocallyadvancedrectalcancerkscc1301 AT okieiji randomizedphaseiistudycomparingtheefficacyandsafetyofsoxversusmfolfox6asneoadjuvantchemotherapywithoutradiotherapyforlocallyadvancedrectalcancerkscc1301 AT enomotomasanobu randomizedphaseiistudycomparingtheefficacyandsafetyofsoxversusmfolfox6asneoadjuvantchemotherapywithoutradiotherapyforlocallyadvancedrectalcancerkscc1301 AT iharakeisuke randomizedphaseiistudycomparingtheefficacyandsafetyofsoxversusmfolfox6asneoadjuvantchemotherapywithoutradiotherapyforlocallyadvancedrectalcancerkscc1301 AT andokoji randomizedphaseiistudycomparingtheefficacyandsafetyofsoxversusmfolfox6asneoadjuvantchemotherapywithoutradiotherapyforlocallyadvancedrectalcancerkscc1301 AT fujitafumihiko randomizedphaseiistudycomparingtheefficacyandsafetyofsoxversusmfolfox6asneoadjuvantchemotherapywithoutradiotherapyforlocallyadvancedrectalcancerkscc1301 AT tominagamasahiro randomizedphaseiistudycomparingtheefficacyandsafetyofsoxversusmfolfox6asneoadjuvantchemotherapywithoutradiotherapyforlocallyadvancedrectalcancerkscc1301 AT morishinichiro randomizedphaseiistudycomparingtheefficacyandsafetyofsoxversusmfolfox6asneoadjuvantchemotherapywithoutradiotherapyforlocallyadvancedrectalcancerkscc1301 AT nakayamagoro randomizedphaseiistudycomparingtheefficacyandsafetyofsoxversusmfolfox6asneoadjuvantchemotherapywithoutradiotherapyforlocallyadvancedrectalcancerkscc1301 AT shimokawamototsugu randomizedphaseiistudycomparingtheefficacyandsafetyofsoxversusmfolfox6asneoadjuvantchemotherapywithoutradiotherapyforlocallyadvancedrectalcancerkscc1301 AT saekihiroshi randomizedphaseiistudycomparingtheefficacyandsafetyofsoxversusmfolfox6asneoadjuvantchemotherapywithoutradiotherapyforlocallyadvancedrectalcancerkscc1301 AT babahideo randomizedphaseiistudycomparingtheefficacyandsafetyofsoxversusmfolfox6asneoadjuvantchemotherapywithoutradiotherapyforlocallyadvancedrectalcancerkscc1301 AT morimasaki randomizedphaseiistudycomparingtheefficacyandsafetyofsoxversusmfolfox6asneoadjuvantchemotherapywithoutradiotherapyforlocallyadvancedrectalcancerkscc1301 AT akagiyoshito randomizedphaseiistudycomparingtheefficacyandsafetyofsoxversusmfolfox6asneoadjuvantchemotherapywithoutradiotherapyforlocallyadvancedrectalcancerkscc1301 |